Fuso Pharmaceutical Industries,Ltd.

Tokyo Stock Exchange 4538.T

Fuso Pharmaceutical Industries,Ltd. Shareholders' Equity for the year ending March 31, 2024: USD 242.22 M

Fuso Pharmaceutical Industries,Ltd. Shareholders' Equity is USD 242.22 M for the year ending March 31, 2024, a -9.73% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

Fuso Pharmaceutical Industries,Ltd. Shareholders' Equity for the year ending March 31, 2023 was USD 268.33 M, a -5.41% change year over year.
Fuso Pharmaceutical Industries,Ltd. Shareholders' Equity for the year ending March 31, 2022 was USD 283.67 M, a -6.74% change year over year.
Fuso Pharmaceutical Industries,Ltd. Shareholders' Equity for the year ending March 31, 2021 was USD 304.17 M, a 1.26% change year over year.
Fuso Pharmaceutical Industries,Ltd. Shareholders' Equity for the year ending March 31, 2020 was USD 300.37 M, a 1.41% change year over year.

Key data

Date	Shareholders' Equity	Minority Interest	Total Equity	Total Stockholders Equity and Liabilities

Tokyo Stock Exchange: 4538.T

Fuso Pharmaceutical Industries,Ltd.

CEO	Mr. Mikio Toda
IPO Date	Jan. 1, 2001
Location	Japan
Headquarters	1-7-10, Doshomachi
Employees	1,370
Sector	Consumers Staples
Industries Cleaning Supplies Automotive Parts Composite Materials Hardware & Electronics Non-Alcoholic Beverages Personal Care Pharmaceuticals Plastics

Description

Fuso Pharmaceutical Industries,Ltd. manufactures and sells pharmaceutical products in Japan. The company offers ethical drugs, such as injectables and artificial kidney dialysates; and medical machinery and equipment. It also rents real estate properties. The company was founded in 1937 and is headquartered in Osaka, Japan.

Key trends

Past 5 years